At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,569 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessing the Impact of MOVALIS on Health Related Quality of Life
In Brief
An observational study for Osteoarthritis and Arthritis, Rheumatoid. Completed, enrolled 3,569 participants across 319 sites in 5 countries.
Detailed Summary
The objective of the observational study is to examine the effect of MOVALIS (Meloxicam) therapy on Health Related Quality of Life (HRQoL) in the diverse region of Central and Eastern Europe. The Medical Outcomes Study 12 Item Short Form Health Survey version 2 (SF-12v2) will be used as the instrument to measure any change in physical wellbeing (Physical Component Summary, PCS) and mental wellbeing (Mental Component Summary, MCS) of patients following MOVALIS (Meloxicam) therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Arthritis, Rheumatoid
CountriesCroatia, Czechia, Estonia, Russia, Slovakia
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedFeb 2008
Primary CompletionMay 2008
TodayJul 2026
First PostedFeb 20, 2008
Enrollment StartMar 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.4 years ago